15% OFF $200+· CodeSTOCKUP15
Ends November 30Shop now
Lot certificates published
Plain, secure packaging
Catalog/Tirzepatide
Tirzepatide
#1002
Lyophilized Peptide

Tirzepatide 30mg

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors: a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications conferring GLP-1 receptor co-agonism. A C20 fatty-diacid moiety linked through a glutamic acid and two mini-PEG spacers enhances albumin binding and in-vitro stability. Supplied strictly for in-vitro research and laboratory use only. Not for human or animal use.

Select Option

Single (30mg)$89.99

2+ save 5% · 5+ save 10% · 10+ save 20%

Quantity

1
= $89.99
Buy now
  • Free Priority shipping on US orders over $100
  • Ships same day on orders before 2 PM MST
  • Plain, secure packaging
  • Reported measurements · lot TIR-20260811-02Bioviridian Inc. · COA7922: purity 99.85%; content 30.60 mg.
  • Stock-solution arithmetic — Tirzepatide concentration calculator

Batch Tracking

Batch #

TIR-20260811-02

Tested

2026-08-23

Purity

99.85%

Method

RP-HPLC (214 nm)

View Certificate of Analysis
Telegram - @purely_peptides orders@purelypeptides.org

Mechanism of Action

In engineered receptor-expressing cell systems, tirzepatide activates GIPR and GLP-1R. Willard et al. (2020) reported GIPR signaling resembling native GIP, while GLP-1R signaling favored cAMP generation over beta-arrestin recruitment and produced less GLP-1R internalization than GLP-1.

Properties

CAS Number

2023788-19-2

Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight

4813.53 Da

Half-Life

~5 days (human)

Storage

Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.

Shipping & Delivery

  • Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
  • US shipping from $5. Free Priority on orders $100+ (before discounts).
  • Plain, unmarked packaging — no branding or product names on the outside.
  • Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Full shipping details

Quality & Testing

  • Independently tested by Bioviridian Inc. — identity by LC-MS/MS, purity by RP-HPLC (214 nm).
  • Reported measurements on lot TIR-20260811-02:Bioviridian Inc. · COA7922: purity 99.85%; content 30.60 mg.
  • USA-based; dispatched from Phoenix, Arizona.
  • Supplied strictly for in-vitro laboratory research — not for human use.
Lot TIR-20260811-02 · certificatesBioviridian Inc. · COA7922: purity 99.85%; content 30.60 mg.

Research Applications

1Dual incretin-receptor signaling analysis
2Comparative pharmacology vs. selective GLP-1 agonists
3Adipose-tissue biology and lipid-pathway research
4Beta-cell function models
5Receptor co-agonism and comorbidity models

References & Citations

(4)
1

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.

Schneck K, Urva S

CPT Pharmacometrics Syst Pharmacol (2024)PMID: 38356317 DOI
2

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Willard FS, Douros JD, Gabe MBN, et al.

JCI Insight (2020)PMID: 32730231 DOI
3

Structural determinants of dual incretin receptor agonism by tirzepatide

Sun B, Willard FS, Feng D, et al.

Proc Natl Acad Sci USA (2022)PMID: 35333651 DOI
4

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

Samms RJ, Christe ME, Collins KA, et al.

J Clin Invest (2021)PMID: 34003802 DOI

Research Use Only

This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.

Research reference

A published identity, mechanism, and bibliography record corresponds to this catalog entry.

Research reference: Tirzepatide

More references from the Research Library (5)

Further papers cited in the Library's Tirzepatide record, each checked against PubMed. They describe the compound in research settings and are not statements about this product. See the full record for its identity, structure and complete bibliography.

  1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

    Coskun T, Sloop KW, Loghin C, et al.

    Molecular metabolism (2018)In vitro · Animal · Human participants (interventional)PMID 30473097
  2. Pharmacology, physiology, and mechanisms of incretin hormone action.

    Campbell JE, Drucker DJ

    Cell metabolism (2013)Review articlePMID 23684623
  3. How May GIP Enhance the Therapeutic Efficacy of GLP-1?

    Samms RJ, Coghlan MP, Sloop KW

    Trends in endocrinology and metabolism: TEM (2020)Review articlePMID 32396843
  4. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.

    Zhang Y, Sun B, Feng D, et al.

    Nature (2017)In vitroPMID 28538729
  5. Structural basis for ligand recognition of incretin receptors.

    Underwood CR, Parthier C, Reedtz-Runge S

    Vitamins and hormones (2010)Review articlePMID 21094903